Can Lung Nodules Shrink? Causes and What Happens Next

Lung nodules can and frequently do shrink, and in many cases they disappear entirely. The majority of small pulmonary nodules found on CT scans turn out to be benign, caused by infections, inflammation, or other non-cancerous processes that the body resolves on its own over weeks to months. Even so, the path from “nodule found” to “nodule gone” is rarely straightforward, and the reasons a nodule shrinks matter as much as the fact that it does.

Why Most Nodules Are Not Cancer

A lung nodule is a small spot, generally under 3 centimeters, that shows up as a white shadow on a chest CT scan. They are remarkably common. Screening programs and routine imaging for unrelated problems catch them regularly, and the vast majority turn out to be harmless. The long list of things that can create a nodule includes infections, non-infectious granulomas, developmental abnormalities, blood vessel malformations, blood clots causing localized tissue damage, lymph nodes sitting inside the lung tissue, rounded patches of collapsed lung, and old scarring from inflammation.¹ Many of these are self-limiting. A fungal infection clears up, and the nodule it left behind either shrinks or calcifies into a tiny, stable scar. An episode of pneumonia leaves a small inflammatory mark that fades within a few months.

In a study of patients with a specific genetic condition affecting the lungs (alpha-1 antitrypsin deficiency), about 13% had a nodule visible on their first CT scan, and over time roughly 27% had at least one nodule appear on some scan. Out of all those nodules, only two turned out to be cancer.² That population has specific risk factors, but the broader point holds: the ratio of benign to malignant nodules found incidentally on imaging is heavily weighted toward benign.

Infections and Inflammation That Resolve

The most common reason a lung nodule shrinks is that it was caused by an infection or inflammatory process that runs its course. Bacterial pneumonia, fungal infections like histoplasmosis or coccidioidomycosis, and even tuberculosis can leave behind nodular marks on imaging. Once the infection is treated or the immune system handles it, the inflamed tissue contracts. Depending on the original size and the type of infection, this can take anywhere from a few weeks to well over a year.

Sarcoidosis is a good example of a non-infectious inflammatory condition that can produce lung nodules mimicking cancer. A solitary mass caused by sarcoidosis can look alarming on a scan, but in some cases these masses regress on their own without any treatment.³ The tricky part is that sarcoidosis nodules and cancerous nodules can look nearly identical on a CT, which is why doctors often pursue further testing rather than simply waiting.

Vaping has emerged as another cause of lung nodules that can resolve. Case reports have documented granulomatous disease in the lungs, a condition where the immune system forms small clumps of inflammatory cells, developing after someone starts vaping and then clearing up after they stop. Unlike granulomatous disease from long-term exposure to things like silica dust, vaping-related granulomas appear to be reversible once the exposure ends.⁴ This is a relatively new area of clinical observation, so the full picture is still taking shape.

What Smoking Cessation Can Do

If you smoke and have been found to have lung nodules, quitting can make a measurable difference. One study specifically looking at smokers who underwent short-term smoking cessation found a statistically significant reduction in the size of their lung nodules.⁵ Smoking causes chronic low-grade inflammation in the airways, and when you remove the irritant, the inflammatory component of certain nodules can subside.

A particularly striking case involved a patient with pulmonary Langerhans cell histiocytosis, a condition strongly linked to smoking. After the patient quit, serial CT scans showed nodules and cysts in the lungs gradually shrinking, with complete clearance of all visible abnormalities after twelve months.⁶ That kind of total resolution is not universal, but it underscores how directly some lung nodules are tied to ongoing tobacco exposure. Quitting does not guarantee your nodules will disappear, but for certain types of inflammatory nodules, removing the stimulus is the single most effective intervention.

Can Cancerous Nodules Shrink on Their Own?

This is the question that tends to generate the most hope and confusion. Spontaneous regression of lung cancer does occur, but it is genuinely rare. Case reports describe patients with confirmed non-small cell lung cancer whose tumors shrank or disappeared without any treatment. In one published case, a patient with lung cancer had spontaneous regression of both the primary tumor and metastatic sites, beginning within a week of having biopsy samples taken. The researchers speculated that the biopsies may have triggered an immune response against the tumor.⁷

The leading theory for why this happens involves the immune system. Researchers believe that immune activation, particularly T-cell responses and the release of certain signaling molecules, can occasionally turn against a tumor effectively enough to cause it to shrink.⁸ A similar pattern has been documented in mesothelioma, where one patient had temporary tumor regression that coincided with the tumor tissue being infiltrated by immune cells and measurable anti-tumor immune activity in the blood. When the tumor eventually progressed again, those immune markers had faded.⁹

These cases are fascinating and they inform how researchers think about immunotherapy, but they are emphatically not something to plan around. Spontaneous cancer regression remains a case-report-level phenomenon. If a nodule is confirmed or strongly suspected to be malignant, waiting and hoping is not a responsible strategy.

Treatment-Driven Shrinkage

When lung nodules do turn out to be cancerous, modern treatments can produce dramatic shrinkage. Targeted therapies have changed the landscape considerably for certain types of lung cancer. For patients whose tumors carry specific genetic mutations, drugs designed to block the molecular driver of the cancer can halt growth and kill cancer cells. In advanced non-small cell lung cancer with certain mutations, targeted drugs have shown superiority over older therapies in shrinking tumors, extending survival, and controlling spread to the brain.¹⁰ Immunotherapy, which works by boosting the body’s own immune response against cancer cells, has added another avenue for nodule reduction in eligible patients.

For benign causes, antibiotics can shrink nodules caused by bacterial infections, antifungal medications handle fungal granulomas, and corticosteroids may reduce nodules tied to inflammatory conditions like sarcoidosis or rheumatoid lung disease. The treatment depends entirely on identifying the cause, which is why the diagnostic workup matters so much.

When a Nodule Only Looks Like It Shrank

Not every apparent change in nodule size is real. CT measurement of small lung nodules is surprisingly imprecise, and what looks like shrinkage on a follow-up scan can sometimes be a measurement artifact. When radiologists measure a nodule’s diameter by hand, small differences in where they place the measurement line or how the patient is positioned can shift the number meaningfully. One study found that diameter-based measurements between different observers could vary by as much as 30% in either direction.¹¹ For a 6-millimeter nodule, a 30% swing could make it appear to have shrunk to around 4 millimeters, or grown to nearly 8, when nothing actually changed.

Volume-based measurements using semi-automated software tend to be more consistent than manual diameter readings, but they are not immune to variability either. Small changes in the scanner settings, the patient’s breathing depth, or how the software outlines the nodule’s edge can all introduce error.¹² This is one reason why radiologists are cautious about declaring a nodule has meaningfully changed size after a single follow-up scan, especially for very small nodules. A real change usually needs to be confirmed over multiple scans or exceed a threshold that goes beyond normal measurement noise.

Newer artificial intelligence tools are being developed to improve this. AI-assisted measurement software has shown slightly better accuracy in identifying cancer and correctly classifying benign nodules compared to unaided radiologists, though the improvement comes with a trade-off of somewhat longer surveillance periods on average.¹³ These tools are not yet standard everywhere, but the direction of the field is clearly toward more automated and reproducible measurements.

How Doctors Decide What to Do Next

Finding a nodule on a CT scan triggers a decision tree that weighs your individual risk against the nodule’s characteristics. The Fleischner Society guidelines, which most radiologists in the U.S. and Europe follow, were updated in 2017 to raise the minimum size threshold for routine follow-up and to give ranges for follow-up timing rather than rigid deadlines. This was meant to reduce unnecessary scanning for tiny, low-risk nodules while still catching the ones that matter.¹⁴ For a solid nodule under 6 millimeters in a low-risk patient, the current recommendation is often no follow-up at all. Larger nodules or those in higher-risk patients get scheduled follow-up scans at intervals of a few months to a year.

Calcification patterns within a nodule can offer strong clues. Certain patterns of calcium deposits, like a diffuse, laminated, or popcorn-like distribution, are characteristic of benign processes and can effectively rule out cancer in many cases.¹⁵ An eccentric calcification pattern, however, is less reassuring and may warrant additional investigation.

When a nodule falls into an ambiguous zone, PET/CT scanning can help. PET imaging detects metabolic activity, and cancer cells tend to consume more glucose than normal tissue, lighting up on the scan. For solid nodules over about 10 millimeters, PET/CT has strong diagnostic performance, with one study reporting a sensitivity of 94% and a negative predictive value of 95%, meaning that a nodule that does not light up on PET is unlikely to be cancer.¹⁶ Combining PET results with how fast the nodule grows (its volume doubling time) makes the assessment even more reliable. A nodule that is PET-negative and growing slowly is very likely benign, while one that is PET-positive and doubling quickly is much more concerning.¹⁷

PET/CT can also change the biopsy plan. In a prospective study of patients whose doctors had initially planned to biopsy a lung nodule, reviewing the PET/CT results changed the management decision in about a quarter of cases. Some patients were switched to observation instead of biopsy, others had the biopsy redirected to a different site, and a smaller group had biopsies added based on PET findings.¹⁸ The upshot is that PET imaging frequently spares patients from invasive procedures they do not need, which is especially relevant when a nodule is already shrinking and the question is whether to biopsy it or continue watching.

The Anxiety of Waiting

One aspect of lung nodules that rarely gets enough attention is the psychological toll of surveillance. Being told you have a spot on your lung and then being told to come back in three to six months for another scan is a deeply unsettling experience for many people. In one quality-improvement study, about 60% of patients with pulmonary nodules reported worrying about them at least once a month, and roughly one in five worried daily. The average self-reported anxiety score was nearly 5 out of 10.¹⁹ That same study found that simply providing patients with a fact sheet about nodules improved anxiety in over 80% of recipients, suggesting that a significant portion of the distress comes from not understanding what a nodule is or what the odds actually are.

A broader review of psychological outcomes in lung cancer screening programs found that the screening process itself did not cause lasting psychological harm for most participants. However, people who received indeterminate or suspicious results did experience elevated anxiety and lung-cancer-specific distress in the short term.²⁰ Demographic factors and smoking status appeared to influence who was more vulnerable to that distress. Current smokers, for instance, may carry extra guilt and fear about what a nodule could mean.

Even in confirmed cancer patients undergoing ongoing surveillance, the anxiety around each scan, sometimes called “scanxiety,” is a real and recurring challenge. Patients describe using a range of coping strategies, and many point to their relationship with their clinician and how results are delivered as factors that either help or worsen their experience.²¹ If you are going through nodule surveillance and find the waiting periods difficult, raising this with your doctor is worthwhile. There are practical steps, from adjusting how and when you receive results to connecting with support resources, that can make the process more manageable.

What Stability Means and How Long You Wait

A nodule that has not changed size over two years of follow-up is generally considered stable and benign. This two-year stability benchmark is one of the foundations of nodule management, and it is also used as a diagnostic endpoint in research. If a solid nodule looks the same on a scan taken 24 months after the first, the probability that it is cancerous drops to very low levels.

Subsolid nodules, which appear hazy or partly transparent on imaging rather than solid white, play by slightly different rules. These nodules can represent a spectrum of conditions from transient inflammation to slow-growing cancers. The slow-growing ones can take years to declare themselves, which is why surveillance intervals for subsolid nodules tend to be longer. Some guidelines recommend watching persistent subsolid nodules for up to five years before concluding they are stable.

For a nodule that is actively shrinking on serial imaging, the clinical significance depends on the context. If you had a recent infection and the nodule is getting smaller, that is strong evidence it was inflammatory and nothing more needs to be done once it resolves. If a nodule of uncertain cause is shrinking but has not disappeared, your doctor will likely continue monitoring until it either vanishes, calcifies into a scar, or reaches a stable size. Partial shrinkage does not automatically rule out cancer. Some malignant nodules can fluctuate slightly in apparent size due to changes in surrounding inflammation or measurement variability, so the trend over multiple scans matters more than any single comparison.

Nodules That Never Shrink but Are Still Benign

Some benign nodules are permanent residents. A healed granuloma from a long-past fungal infection may calcify and sit in your lung tissue for the rest of your life, never growing, never shrinking, never causing any problems. Hamartomas, which are benign growths made up of a mix of tissue types, tend to be stable over time and sometimes show a characteristic “popcorn” calcification pattern on CT that helps identify them without a biopsy. Intrapulmonary lymph nodes, small bits of immune tissue that happen to sit inside the lung rather than in the usual locations, are another common cause of stable, harmless nodules.

Having a stable nodule on your imaging is not a medical problem in itself. The only practical implication is that if you have future CT scans for any reason, whoever reads them should know the nodule is there and has been previously evaluated. This avoids the situation where a new doctor sees the old nodule, does not know its history, and initiates a new round of workup for something that was settled years ago. Keeping a record of your imaging history, or at least knowing the dates and locations of past scans, can prevent that kind of unnecessary repeat evaluation.